Top Markets
#1 Derive Derive +33.82%
#2 Cross Cross +15.09%
#3 Geodnet Geodnet +13.37%
#4 Gama Token Gama Token +9.17%
#5 Talus Network Talus Network +8.96%
#6 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +7.42%
#7 Cap Cap +6.96%
#8 Audiera Audiera +5.78%
#9 OVERTAKE OVERTAKE +5.63%
#10 Ontology Gas Ontology Gas +5.54%
Coin of the day
Derive Derive
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Classificação em ações #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preço da ação
$1.73
Última sincronização: 2025-06-17
Valor de mercado
$2.55M
Variação (1 dia)
-0.29%
Variação (1 ano)
0.00%
País
US
Negociar Eiger BioPharmaceuticals, Inc. (EIGR)

Categoria

Healthcare
Lucros da Eiger BioPharmaceuticals, Inc. (EIGR)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Eiger BioPharmaceuticals, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Eiger BioPharmaceuticals, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE